[PDF] Top 20 Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
Has 10000 "Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)" found on our website. Below are the top 20 most common "Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)".
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
... of Thoracic Oncology. A total of 80 mg and 160 mg daily doses were used. Five out of 60 patients were EGFR T790M positive. The ORR was 77% (67% at 80 mg dose and 87% at 160 mg dose). Overall PFS was 19.3 ... See full document
10
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
... as AZD9291) is the newest FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) ... See full document
13
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
... T790M mutation is the most common mechanism of re- sistance to the first- and second-generation of epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKI) ... See full document
5
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
... EGFR-TKIs: epidermal growth factor receptor tyrosine kinase inhibitors; PHGDH: phosphoglycerate dehydrogenase; NSCLC: non-small cell lung cancer; SCLC: ... See full document
16
<p>Treatment Response To Osimertinib In <em>EGFR</em>-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series</p>
... from non-small cell lung cancer (NSCLC) is challenging, and conventional treatments have little impact on the disease ...a mutation of epidermal growth ... See full document
6
<p>Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date</p>
... of lung cancers with onco- genic mutations, achieving notably improved progression-free (PFS) and overall survival (OS) rates compared to reference chemotherapy ...of metastatic non-small – ... See full document
16
Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review
... specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating tumor cells for detecting the epidermal growth factor receptor ... See full document
12
Development of personalized treatments in lung cancer: focusing on the <em>EGFR</em> mutations and beyond
... EGFR, epidermal growth factor receptor; HR, hazard ratio; N/A, not applicable; OS, overall survival; PFS, progression-free survival; TKi, tyrosine kinase inhibitor; iPASS, iReSSA Pan-Asian ... See full document
11
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
... for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, respectively; 44 (42%) had EGFR-positive NSCLC and 2 (8%) had ... See full document
16
<p>Predictors of Acquired <em>T790M</em> Mutation in Patients Failing First- or Second-Generation <em>Epidermal</em> <em>Growth</em> <em>Factor</em> <em>Receptor</em>-Tyrosine Kinase Inhibitors</p>
... NSCLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase; TKIs, ... See full document
12
Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France : African women exhibit a mutational spectrum more similar to Asians than to Caucasians
... of non-white Europeans, despite the multicultural milieu observed in the greater Paris region ...relatively small number of patients of Asian descent in our study, the estimation of the frequency of rare ... See full document
13
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
... growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) brought new hope to advanced NSCLC ...their small molecular weight and ability to penetrate BBB to some extent, provided a certain ... See full document
7
Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
... that blood sample may replace biopsy samples for Chinese NSCLC patients to detect EGFR mutations with qualified techniques. Many techniques such as high-resolution melting analysis, immunohistochemistry, polymerase chain ... See full document
10
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
... important unanswered questions remain, including how to determine which patients and which tumors are the best candidates for these therapies; clearly, identifying antian- giogenesis biomarkers will be an essential ... See full document
13
Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
... EGFR mutation type, first-line treatment, therapy for BM, RT types, and interval between RT and ...EGFR mutation type (exon 19 deletion, exon 21 L858R mutation), first-line treatment (chemotherapy, ... See full document
7
Original Article EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence
... able lung cancer is up to 20%; in Poland, according to the National Lung Cancer Registry data, not more than 17% of NSCLC are resect- ed [7] and for other patients the only source of malignant ... See full document
13
Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment
... for lung [29, 30], head and neck [31] and colorectal adenocarcinomas ...germline mutation and occurrence frequency is comparable for cancer and healthy subjects ...between lung adenocarcinoma ... See full document
7
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
... EGFR mutation T790M, substituting threonine for methionine at pos- ition 790 in exon ...EGFR T790M positive NSCLC is represented by the development of third-generation EGFR TKIs, which include ... See full document
14
Detection of <em>EML4-ALK</em> fusion gene and features associated with <em>EGFR</em> mutations in Chinese patients with non-small-cell lung cancer
... and histology, but no significant association was observed between EML4-ALK fusion gene and clinical stage. A total of 147 (21.18%) patients had EGFR mutations. In concordance with previous reports, EGFR mutation ... See full document
7
<em>EGFR </em>mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
... EGFR mutation was detected in 29 out of 639 patients with ...only factor associated with a significantly better OS of ...19 mutation and nonsmoking status were associated with significantly better ... See full document
5
Related subjects